Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Tarsus Pharmaceuticals in a report issued on Wednesday, February 26th. HC Wainwright analyst O. Livnat anticipates that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright currently has a "Buy" rating and a $73.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS and FY2027 earnings at $4.14 EPS.
Several other research analysts also recently issued reports on TARS. The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Barclays reduced their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, Guggenheim reiterated a "buy" rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $61.33.
Read Our Latest Analysis on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Price Performance
Shares of Tarsus Pharmaceuticals stock traded up $1.83 during trading on Friday, reaching $44.55. The company's stock had a trading volume of 394,769 shares, compared to its average volume of 642,828. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28. The stock has a market capitalization of $1.71 billion, a P/E ratio of -11.75 and a beta of 1.01. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a 50-day moving average price of $50.74 and a two-hundred day moving average price of $43.48.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to analysts' expectations of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. increased its position in shares of Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after acquiring an additional 244 shares in the last quarter. Sherbrooke Park Advisers LLC boosted its position in shares of Tarsus Pharmaceuticals by 7.2% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company's stock worth $364,000 after buying an additional 443 shares during the period. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. Bank of New York Mellon Corp lifted its position in shares of Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after purchasing an additional 498 shares in the last quarter. Finally, Swiss National Bank lifted its position in Tarsus Pharmaceuticals by 1.2% during the 4th quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after buying an additional 600 shares in the last quarter. Institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Stories
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
